Can immune monitoring unlock better treatments for deadly mold infections?
NCT ID NCT06285188
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study monitors the immune system of 20 adults with serious mold infections (like Aspergillus) to see how their T cells respond. The goal is to find out which patients might benefit from adding immunotherapy to standard antifungal drugs. Researchers will measure immune checkpoint molecules on T cells over time. This is an observational study, not a treatment trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FUSARIOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Necker Enfants Malades
RECRUITINGParis, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test outsmart deadly fungal infections in blood cancer?
- Can a gentler antifungal drug protect liver transplant patients from deadly mold without risking organ rejection?
- New PET tracer could spot hidden fungal infections
- Custom 3D-Printed titanium implants could rebuild faces after injury or surgery
- Hospital study tracks deadly fungus and a possible predictor of patient outcomes
- New antifungal drug shows promise against deadly fungal infections